Catalyst Financial Partners LLC Has $553,000 Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Catalyst Financial Partners LLC boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,639 shares of the medical equipment provider’s stock after purchasing an additional 33 shares during the period. Catalyst Financial Partners LLC’s holdings in Intuitive Surgical were worth $553,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. OFI Invest Asset Management bought a new position in shares of Intuitive Surgical in the third quarter worth about $25,000. Baystate Wealth Management LLC boosted its position in Intuitive Surgical by 150.0% in the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the last quarter. MCF Advisors LLC raised its position in shares of Intuitive Surgical by 108.1% during the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 40 shares during the last quarter. Headinvest LLC acquired a new position in shares of Intuitive Surgical during the third quarter valued at $28,000. Finally, Stone House Investment Management LLC increased its position in Intuitive Surgical by 100.0% in the third quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 50 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 1.3 %

Shares of NASDAQ ISRG traded up $5.08 during trading hours on Thursday, hitting $385.45. The company had a trading volume of 882,172 shares, compared to its average volume of 1,594,653. The firm’s 50 day moving average is $385.21 and its 200-day moving average is $352.17. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The stock has a market capitalization of $136.72 billion, a P/E ratio of 69.58, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue was up 11.5% on a year-over-year basis. During the same period last year, the firm posted $1.00 earnings per share. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In related news, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Intuitive Surgical news, EVP Myriam Curet sold 481 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $386.09, for a total transaction of $185,709.29. Following the sale, the executive vice president now directly owns 298 shares in the company, valued at $115,054.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Insiders have sold a total of 147,927 shares of company stock worth $57,064,459 over the last ninety days. Insiders own 0.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ISRG shares. Truist Financial increased their price objective on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Jefferies Financial Group lifted their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday, April 19th. Citigroup upped their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada upped their price objective on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research report on Wednesday, January 24th. Finally, Barclays raised their price objective on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.